The hypercholesterolemia market is expected to grow in the
coming years due to an increase in the prevalent cases of
hypercholesterolemia, along with the expected launch of emerging
therapies.
LAS
VEGAS, May 23, 2024 /PRNewswire/ --
DelveInsight's Hypercholesterolemia Market
Insights report includes a comprehensive understanding of
current treatment practices, hypercholesterolemia emerging drugs,
market share of individual therapies, and current and forecasted
market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Hypercholesterolemia Market
Report
- According to DelveInsight's analysis, the market size for
hypercholesterolemia is expected to grow significantly by
2034.
- As per DelveInsight's estimates, the prevalence of
hypercholesterolemia in the US indicates that it is most commonly
observed in the age group ranging from 45 to 64, suggesting
a higher prevalence among the older population.
- Leading hypercholesterolemia companies such as Novartis
Pharmaceuticals, Merck Sharp & Dohme LLC, Esperion
Therapeutics, Inc., Arrowhead Pharmaceuticals, LIB Therapeutics
LLC, Medpace, Inc., AstraZeneca, NewAmsterdam Pharma, and
others are developing novel hypercholesterolemia drugs that can be
available in the hypercholesterolemia market in the coming
years.
- The promising hypercholesterolemia therapies in the pipeline
include Inclisiran, MK-0616, Bempedoic acid, ARO-ANG 3,
Lerodalcibep, AZD0780, Obicetrapib, among others.
Discover which therapies are expected to grab the major
hypercholesterolemia market share @ Hypercholesterolemia
Market Report
Hypercholesterolemia Overview
Hypercholesterolemia is marked by abnormally high cholesterol
levels in the bloodstream. Cholesterol, a fatty substance, is both
produced internally and sourced from certain foods like egg yolks,
meat, and dairy. Genetic mutations, such as those in genes like
APOB, LDLR, LDLRAP1, and PCSK9, are primary contributors to this
condition. Lifestyle factors such as diet, exercise habits, and
smoking also play a significant role. Additional influences on
cholesterol levels include gender, age, and health conditions like
diabetes and obesity. Symptoms may manifest as chest pain and the
formation of small, waxy bumps known as xanthomas, typically found
on the hands, elbows, knees, or around the eyes. Diagnosis relies
on blood tests to measure levels of "bad" cholesterol, encompassing
triglycerides and low-density lipoproteins (LDLs), as well as the
presence of "good" cholesterol, known as high-density lipoprotein
(HDL).
Hypercholesterolemia Epidemiology Segmentation
The hypercholesterolemia epidemiology section provides insights
into the historical and current hypercholesterolemia patient pool
and forecasted trends for the 7MM. It helps recognize the causes of
current and forecasted patient trends by exploring numerous studies
and views of key opinion leaders.
The hypercholesterolemia market report proffers
epidemiological analysis for the study period 2020–2034 in the 7MM
segmented into:
- Total Prevalent Cases of Hypercholesterolemia
- Gender-specific Prevalent Cases of Hypercholesterolemia
- Age-specific Prevalent Cases of Hypercholesterolemia
- Type-specific Prevalent Cases of Hypercholesterolemia
- Diagnosed and Treatable Cases of Hypercholesterolemia
Hypercholesterolemia Treatment Market
The treatment approach for hypercholesterolemia, including its
various forms like Homozygous and Heterozygous Familial
Hypercholesterolemia, encompasses several options on the market.
These include statins, bile-acid-binding resins, cholesterol
absorption inhibitors, combinations of cholesterol absorption
inhibitors with statins, Proprotein Convertase Subtilisin/Kexin
Type 9 (PCSK9) inhibitors, and injectable medications. Among the
FDA-approved drugs for hypercholesterolemia, statins are the most
widely utilized, either alone or in combination with other
medications. Statins work by inhibiting the enzyme
3-hydroxy-3-methylglutaryl coenzyme A reductase and offer various
benefits in managing atherosclerosis, such as stabilizing plaques,
reducing platelet activation, and mitigating plaque growth and
inflammation. Additionally, statins provide further advantages
beyond atherosclerotic plaque management, including anticoagulant
effects, vasodilation, antioxidant properties, and reducing
inflammatory mediators.
In February 2020, the FDA
approved Esperion Therapeutics, Inc. for two medications:
NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and
ezetimibe) tablets. These drugs are intended to be used
alongside dietary measures and statin therapy for managing primary
hyperlipidemia in adults with either heterozygous familial
hypercholesterolemia (HeFH) or atherosclerotic cardiovascular
disease, who require further reduction of LDL-C levels.
In December 2021, the FDA
also approved Novartis's LEQVIO (inclisiran), the
first-in-class siRNA, designed to lower low-density lipoprotein
cholesterol (LDL-C). Furthermore, in July
2023, the FDA expanded the indication for LEQVIO to
encompass the treatment of adults with elevated LDL-C levels who
face an increased risk of heart disease.
To know more about hypercholesterolemia treatment guidelines,
visit @ Hypercholesterolemia Management
Hypercholesterolemia Pipeline Therapies and Key
Companies
- Inclisiran: Novartis Pharmaceuticals
- MK-0616: Merck Sharp & Dohme LLC
- Bempedoic acid: Esperion Therapeutics, Inc.
- ARO-ANG 3: Arrowhead Pharmaceuticals
- Lerodalcibep: LIB Therapeutics LLC/Medpace, Inc.
- AZD0780: AstraZeneca
- Obicetrapib: NewAmsterdam Pharma
Learn more about the FDA-approved drugs for hypercholesterolemia
@ Drugs for Hypercholesterolemia Treatment
Hypercholesterolemia Market Dynamics
The dynamics of the hypercholesterolemia market are expected to
change in the coming years. With lifestyle changes, such as
sedentary habits and unhealthy dietary patterns becoming more
prevalent, the demand for effective cholesterol-lowering
drugs continues to rise. Pharmaceutical companies are actively
engaged in research and development to introduce innovative
therapies targeting different aspects of cholesterol metabolism,
aiming for enhanced efficacy and reduced side effects.
Additionally, stringent regulations and guidelines for
cholesterol management drive the hypercholesterolemia market,
prompting companies to invest in clinical trials and regulatory
approvals to ensure product safety and efficacy.
Moreover, the hypercholesterolemia market dynamics are also
shaped by evolving treatment paradigms and the competitive
landscape. The introduction of novel therapeutic approaches, such
as PCSK9 inhibitors and RNA-based therapies, has expanded
treatment options beyond traditional statins, offering alternatives
for patients who are intolerant or unresponsive to conventional
medications.
Furthermore, many potential therapies are being investigated for
the treatment of hypercholesterolemia, and it is safe to predict
that the treatment space will significantly impact the
hypercholesterolemia market during the forecast period.
Moreover, the anticipated introduction of emerging therapies
with improved efficacy and a further improvement in the
diagnosis rate are expected to drive the growth of the
hypercholesterolemia market in the 7MM.
However several factors may impede the growth of the
hypercholesterolemia market. Firstly, despite advancements in
treatment options such as statins, there remains a significant
unmet need for patients who do not respond well to standard
therapies or experience intolerable side effects. Additionally,
high drug development costs and stringent regulatory
requirements pose challenges for companies seeking to bring new
therapies to market. Moreover, there's a lack of awareness
among patients about the importance of managing cholesterol levels
and adhering to treatment plans, which can hinder effective disease
management.
Moreover, hypercholesterolemia treatment poses a
significant economic burden and disrupts patients' overall
well-being and QOL. Furthermore, the
hypercholesterolemia market growth may be offset by
failures and discontinuation of emerging therapies,
unaffordable pricing, market access and reimbursement
issues, and a shortage of healthcare specialists. In
addition, the undiagnosed, unreported cases and the
unawareness about the disease may also impact the
hypercholesterolemia market growth.
Hypercholesterolemia
Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key
Hypercholesterolemia Companies
|
Novartis
Pharmaceuticals, Merck Sharp & Dohme LLC, Esperion
Therapeutics, Inc., Arrowhead Pharmaceuticals, LIB Therapeutics
LLC, Medpace, Inc., AstraZeneca, NewAmsterdam Pharma,
and others
|
Key Pipeline Hypercholesterolemia Therapies
|
Inclisiran, MK-0616,
Bempedoic acid, ARO-ANG 3, Lerodalcibep, AZD0780,
Obicetrapib, and others
|
Scope of the Hypercholesterolemia Market
Report
- Therapeutic Assessment:
Hypercholesterolemia current marketed and emerging
therapies
- Hypercholesterolemia Market
Dynamics: Key Market Forecast Assumptions of Emerging
Hypercholesterolemia Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views,
Hypercholesterolemia Market Access and Reimbursement
Discover more about hypercholesterolemia drugs in
development @ Hypercholesterolemia Clinical Trials
Table of Contents
1.
|
Hypercholesterolemia Key Insights
|
2.
|
Hypercholesterolemia Report Introduction
|
3.
|
Hypercholesterolemia
Overview at a Glance
|
4.
|
Hypercholesterolemia Executive Summary
|
5
|
Hypercholesterolemia Key Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Hypercholesterolemia Treatment and Management
|
8.
|
Hypercholesterolemia
Guidelines
|
9.
|
Hypercholesterolemia Epidemiology and Patient Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in
Hypercholesterolemia
|
12.
|
Hypercholesterolemia
Marketed Drugs
|
13.
|
Hypercholesterolemia Emerging Drugs
|
14.
|
7MM Hypercholesterolemia Market Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Hypercholesterolemia Pipeline
Hypercholesterolemia Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key hypercholesterolemia companies,
including Novartis Pharmaceuticals, Merck Sharp & Dohme LLC,
Esperion Therapeutics, Inc., Arrowhead Pharmaceuticals, LIB
Therapeutics LLC, Medpace, Inc., AstraZeneca, NewAmsterdam
Pharma, among others.
Hypercholesterolemia Epidemiology Forecast
Hypercholesterolemia Epidemiology Forecast –
2032 report delivers an in-depth understanding of the
disease, historical and forecasted hypercholesterolemia
epidemiology in the 7MM, i.e., the United
States, EU5 (Germany,
Spain, Italy, France, and the United Kingdom), and Japan.
Familial Hypercholesterolemia Market
Familial Hypercholesterolemia Market Insights, Epidemiology,
and Market Forecast – 2032 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key familial hypercholesterolemia companies,
including Sanofi, Regeneron Pharmaceuticals, Amgen, Esperion
Therapeutics, Aegerion Pharmaceutical, Esperion Therapeutics,
Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo
Pharmaceuticals, Arrowhead Pharmaceuticals, among others.
Homozygous Familial Hypercholesterolemia Market
Homozygous Familial Hypercholesterolemia Market Insights,
Epidemiology, and Market Forecast – 2032 report delivers an
in-depth understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key homozygous familial
hypercholesterolemia companies, including Arrowhead
Pharmaceuticals, Novartis, Alnylam Pharmaceuticals, LIB
Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/hypercholesterolemia-market-is-predicted-to-exhibit-remarkable-growth-by-2034-predicts-delveinsight--key-companies----novartis-pharmaceuticals-merck-sharp--dohme-esperion-therapeutics-arrowhead-pharmaceuticals-lib-therapeut-302153729.html
SOURCE DelveInsight Business Research, LLP